Fasenra (benralizumab) was approved by the U.S. Food and Drug Administration (FDA) on November 3, 2017 [1].
What is Fasenra used for?
Fasenra is a prescription medication used to treat severe eosinophilic asthma in adults and children 12 years of age and older [1]. It is intended as an add-on maintenance treatment for patients whose asthma is not adequately controlled with their current asthma medications [1].
How does Fasenra work?
Fasenra targets and depletes eosinophils, a type of white blood cell that plays a role in inflammation in severe asthma [1]. By reducing the number of eosinophils, Fasenra helps to decrease the frequency of asthma exacerbations [1].
When does Fasenra patent expire?
Information regarding Fasenra's patent expiry can be found on DrugPatentWatch.com [2]. Patents protect the exclusivity of a drug, and their expiry can allow for the development of generic or biosimilar versions [2].
Who manufactures Fasenra?
Fasenra is manufactured by AstraZeneca [1].
What are the risks associated with Fasenra?
Like all medications, Fasenra carries potential risks. Common side effects include headache and injection site reactions [1]. More serious, though less common, side effects can occur [1]. It is important to discuss all potential risks and benefits with a healthcare provider [1].
How is Fasenra administered?
Fasenra is administered as a subcutaneous injection [1]. It is typically given every four weeks for the first three doses, and then every eight weeks thereafter [1].
What clinical data supports Fasenra's approval?
The FDA's approval of Fasenra was based on clinical trial data demonstrating its efficacy in reducing asthma exacerbations and improving lung function in patients with severe eosinophilic asthma [1].
How does Fasenra compare to other asthma treatments?
Fasenra is a targeted biologic therapy, differing from inhaled corticosteroids or other asthma medications that may not specifically address eosinophilic inflammation. Its effectiveness is particularly noted in patients with high eosinophil counts [1].
What is the cost of Fasenra?
The cost of Fasenra can vary depending on insurance coverage and other factors. Patients seeking information on pricing and potential financial assistance programs should consult with their healthcare provider or AstraZeneca's patient support services.
Sources:
[1] https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-fasenra-benralizumab-treat-severe-eosinophilic-asthma
[2] https://www.drugpatentwatch.com/